SAKILA RAI: Open Payments
NPI 1285408799 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$281 in 12 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $140 · 2025 $281
Food & beverage: $281
| Company | Payments | Amount |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 2 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Exelixis Inc. | 2 | $38 |
| Syndax Pharmaceuticals, Inc. | 1 | $33 |
| PFIZER INC. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| Merck Sharp & Dohme LLC | 1 | $19 |
Products named: QINLOCK, LIBTAYO, CABOMETYX, INLYTA, Xtandi, XPOVIO, PLUVICTO, KEYTRUDA.
Industry payments across TX — which companies pay providers there.
